Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03183245
Other study ID # CLN-PRO-V007
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date September 29, 2017
Est. completion date September 2029

Study information

Verified date September 2023
Source Humacyte, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access


Description:

This is a Phase 3, prospective, multicenter, open-label, randomized, two-arm, comparative study. Subjects who sign informed consent will undergo study-specific screening assessments within 45 days from the day of informed consent. Eligible study subjects will be randomized to receive either an HAV or AVF. The randomization will be stratified by upper arm or forearm placement based on the investigator's determination of where the study access (SA) should be located. Subjects will be followed to 24 months post SA creation at routine study visits regardless of patency status. After 24 months, AVF subjects with a patent SA will be followed (while the SA remains patent) for up to 5 years (60 months) post SA creation at routine study visits. After 24 months, HAV subjects will be followed (regardless of SA patency) for 5 years (60 months) post SA creation at routine study visits.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 240
Est. completion date September 2029
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects with end-stage renal disease (ESRD), receiving HD via DC and are suitable for the creation of an AVF or implantation of AVG for HD access. 2. Subjects who plan to undergo HD at a dialysis unit of a participating dialysis provider for at least the first 6 months after SA creation. 3. Subjects aged at least 18 years at Screening. 4. Suitable anatomy for creation of a forearm or upper arm AVF and for implantation of straight or looped HAV in either the forearm or upper arm. 5. Hemoglobin =8 g/dL and platelet count =100,000 /mm3. 6. International Normalized Ratio (INR) = 1.5. 7. Female subjects must be either: 1. Of non-childbearing potential, which is defined as post-menopausal (at least 1 year without menses prior to Screening) or documented surgically sterile or post hysterectomy (at least 1 month prior to Screening). 2. Or, of childbearing potential, in which case: i. Must have a negative urine or serum pregnancy test at Screening, and ii. Must agree to use at least one form of the following birth control methods for the duration of the study: - Established use of oral, injectable or implanted hormonal methods of contraception. - Placement of an intrauterine device or intrauterine system. - Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/ gel/ film/ cream/ suppository. 8. Subject, or legal representative, able to communicate effectively with investigative staff, competent and willing to give written informed consent, and able to comply with entire study procedures including all scheduled follow-up visits. 9. Life expectancy of at least 2 years. Exclusion Criteria: 1. Subjects who are optimal candidates for radiocephalic AVF as indicated by meeting ALL of the following criteria: 1. No previous failed AVF. 2. Cephalic vein diameter on ultrasound of more than 3.5mm. 3. Radial artery diameter on ultrasound of more than 3mm. 4. Vein depth of less than 0.5cm from the skin. 5. Normal Allen's test indicating that ulnar artery flow to the hand is sufficient. 6. No calcification in the wall of the distal radial artery. 7. Sufficient length of the proposed fistula outflow vein to provide an adequate (at least 6 cm) cannulation segment. 8. No evidence of iatrogenic injury to target artery or vein. 2. Uncontrolled diabetes; a. HbA1c >10% (at Screening). 3. History or evidence of severe peripheral arterial disease in the extremity selected for implant. 4. Known or suspected central vein stenosis or obstruction on the side of planned SA creation, unless corrected prior to randomization. 5. Planned AVF creation that requires more than one stage to complete. (e.g. basilic vein transposition AVF performed in 2 stages). 6. Planned AVF creation by means other than suture or vascular anastomotic clips (e.g. endovascular surgery or other anastomotic creation devices). 7. Treatment with any investigational drug or device within 60 days prior to study entry (Day 0) or ongoing participation in a clinical trial of an investigational product. 8. Cancer that is actively being treated with a cytotoxic agent. 9. Documented hyper-coagulable state. 10. Bleeding diathesis. 11. Active clinically significant immune-mediated disease, not controlled by maintenance immunosuppression. 1. Low dose glucocorticoid therapy (e.g. 5-10mg prednisone [Deltason]) is acceptable. 2. High dose glucocorticoid therapy for treatment of autoimmune flare, or other inflammatory diseases is excluded. 3. Patients using glucocorticoids for immunosuppression post-transplant to prevent against transplanted allograft rejection in the period post allograft failure are excluded. 4. The following examples of immunosuppressive agents (or the like) are exclusionary for enrollment in this clinical trial: - tacrolimus or FK506 [Prograf] - mycophenolate mofetil [Cellcept], - cyclosporine [Sandimmune or Gengraf] - sirolimus [Rapamune] (this only includes systemically administered, drug eluting stents are acceptable) 12. Anticipated renal transplant within 6 months. 13. History of heparin-induced thrombocytopenia. 14. Venous outflow from SA cannot be located more centrally than the venous outflow of any previous failed access in that extremity. 15. Active local or systemic infection (white blood cells [WBC] > 15,000 cells/mm3 at Screening). If the infection resolves, the subject must be at least one week post resolution of that infection before SA creation. 16. Known serious allergy or intolerance to aspirin and alternative antiplatelet therapy. 17. Pregnant women, or women intending to become pregnant during the course of the trial. 18. Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of the SA. 19. Previous enrollment in this study or any other study with HAV. 20. Employees of Humacyte and employees or relatives of an investigator.

Study Design


Intervention

Biological:
Human Acellular Vessel (HAV)
Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
Procedure:
Arteriovenous fistula (AVF)
Surgical creation of an autologous arteriovenous fistula and subsequent use of the implanted vascular conduit for hemodialysis vascular access.

Locations

Country Name City State
United States Grady Memorial Hospital Atlanta Georgia
United States Brigham and Women's Hospital Boston Massachusetts
United States Surgical Specialists of Charlotte Charlotte North Carolina
United States The Vascular Experts Darien Connecticut
United States Decatur Memorial Hospital Decatur Illinois
United States Denver Health Medical Center Denver Colorado
United States University of California, Irvine Irvine California
United States University of Tennessee Knoxville Knoxville Tennessee
United States University of CA, San Diego - LaJolla VA Hospital La Jolla California
United States University of California San Diego, Jacobs Medical Center La Jolla California
United States Alliance Research Laguna Hills California
United States United Surgical Associates Lexington Kentucky
United States VA Long Beach Healthcare System Long Beach California
United States University of Southern California Los Angeles California
United States South Plains Surgery Center Lubbock Texas
United States Rutgers University Newark New Jersey
United States The Regional Medical Center Orangeburg South Carolina
United States Huntington Hospital Pasadena California
United States Memorial Healthcare System Pembroke Pines Florida
United States Coastal Vascular & Interventional, PLLC Pensacola Florida
United States Arizona Kidney Disease and Hypertension Center (AKDHC) Phoenix Arizona
United States VA Pittsburgh Pittsburgh Pennsylvania
United States Kaiser Permanente Sunnsyide Portland Oregon
United States UC Davis Sacramento California
United States Balboa Nephrology San Diego California
United States Mills Peninsula Hospital San Mateo California
United States Overlook Medical Center Summit New Jersey
United States Olive View- UCLA Medical Center Sylmar California
United States Tampa General Hospital Tampa Florida
United States University of Arizona Tucson Arizona
United States Kidney Care & Transplant Services of New England West Springfield Massachusetts

Sponsors (3)

Lead Sponsor Collaborator
Humacyte, Inc. California Institute for Regenerative Medicine (CIRM), CTI Clinical Trial and Consulting Services

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects with functional patency at 6 months post study access (SA) creation Co-primary endpoint #1: Proportion of subjects with functional patency at 6 months post study access (SA) creation
The definition of "functional patency" is: Dialysis with "2 needles for =75% of dialysis sessions over a continuous 4-week period and either: (1) 4 consecutive sessions during the 4-week period in which 2 needles are used and the mean dialysis machine blood pump speed is =300 mL/min, or (2) a measured spKt/Vurea is = 1.4 or urea reduction ratio >70% during any session in which 2 needles are used within the 4-week period. SpKt/Vurea is calculated from pre and post-treatment serum urea nitrogen concentrations, body weight, and dialysis session duration."
The functional patency ascertainment period will take place between the 1st day of Week 21 (Day 140) and the last day of Week 26 (Day 181) after AVF creation or HAV placement. The endpoint is met when the functional patency criteria are satisfied within any consecutive 4 week period within this ascertainment period.
6 months post SA creation
Primary Proportion of subjects with secondary patency of SA at 12 months post SA creation. Co-primary endpoint #2: Proportion of subjects with secondary patency of SA at 12 months post SA creation.
The SA maintains secondary patency until it is abandoned, irrespective of interventions to maintain or restore patency.
Abandonment is defined as AVF or HAV that can no longer be used for 2-needle, prescribed dialysis as it may be unable to provide adequate flows and/or is deemed unsafe for the subject, and the associated problem cannot be corrected by any intervention, including medical, surgical, or radiological interventions or rest.
12 months post SA creation
Secondary Time to loss of secondary patency (abandonment). 12, 24, and 60 months post SA creation
Secondary Incidence rate of HD access related interventions over the period from SA creation until SA abandonment or 12 months post SA creation 12 months post SA creation
Secondary Incidence rate of infections related to any HD access in situ over the period from SA creation until 12 months post SA creation, irrespective of SA abandonment. 12 months post SA creation
Secondary Proportion of subjects with unassisted functional patency at 6 months post SA creation. 6 months post SA creation
Secondary Incidence rate of HD access-related interventions over the period from SA creation until SA abandonment or the conclusion of the suitability ascertainment period (6 months). 6 months post SA creation
Secondary Time to loss of primary unassisted patency 12, 24, and 60 months post SA creation
Secondary Proportion of HD sessions completed via DC (1 or 2 lines) over the period from SA creation until 12 months post SA creation, irrespective of SA abandonment. 12 months post SA creation
Secondary Number of days with DC in situ "catheter contact time" over the period from SA creation until 12 months post SA creation, irrespective of SA abandonment 12 months post SA creation
Secondary Histopathological remodeling of HAV and AVF - based on histological examination of SA samples explanted for clinical reasons 12, 24, and 60 months post SA creation
Secondary Incidence rate of HD access-related infections over the period from SA creation until SA abandonment. 12, 24, and 60 months post SA creation
Secondary Incidence rate of clinically significant aneurysm or pseudoaneurysm over the period from SA creation until SA abandonment 12, 24, and 60 months post SA creation
Secondary Incidence rate of SA site infections (CDC definition) over the period from SA creation until SA abandonment. 12, 24, and 60 months post SA creation
Secondary Frequency and severity of AEs. 12, 24, and 60 months post SA creation
See also
  Status Clinical Trial Phase
Completed NCT04076488 - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases N/A
Completed NCT03289650 - Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Phase 3
Completed NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Phase 1/Phase 2
Completed NCT01242904 - Use of a Bimodal Solution for Peritoneal Dialysis Phase 2
Completed NCT03257410 - Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Withdrawn NCT02130817 - Belatacept in Kidney Transplantation of Moderately Sensitized Patients Phase 4
Completed NCT05540457 - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis) N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Recruiting NCT02176434 - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease N/A
Active, not recruiting NCT02581449 - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis Phase 2
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02832466 - Quantifying the Deterioration of Physical Function in Renal Patients N/A
Completed NCT02832440 - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis N/A
Completed NCT02830490 - Reliability of Functional Measures in Hemodialysis Patient. N/A
Completed NCT02215655 - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence N/A
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A
Withdrawn NCT01855334 - L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD Phase 4